ImmunityBio, Inc. is a high-risk pharmaceutical company based in the United States that specializes in developing cutting-edge immuno- and cellular therapies to boost the natural immune system. With a focus on ESG sustainability, ImmunityBio's innovative platforms include antibody-cytokine fusion proteins, vaccines, and cell therapies targeted at various cancers. Their top revenue comes from Europe, making it a key market for the company.